Abstract

Although today's cornerstone therapies for asthma (inhaled bronchodilators and corticosteroids) target airway narrowing and lung inflammation, about half of treated asthmatic patients do not achieve good disease control. There is a clear need for new therapeutic approaches and novel drug targets. Recent research has unexpectedly revealed that certain taste receptors (particularly those involved in bitter taste transduction) are expressed in lung tissue. Bitter taste receptors are expressed in several cell types in the lungs (such as chemosensory cells, epithelial cells, smooth muscle cells, lymphocytes, and macrophages) and variously involved in ciliary beating, muscle relaxation, and/or inhibition of the production of inflammatory mediators. Here, we review recent research on the role of bitter taste receptors in experimental models of asthma and in asthmatics. The currently available data suggest that bitter taste receptor agonists have therapeutic potential in chronic obstructive airway diseases such as asthma.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call